2-piperidone has been researched along with Diffuse Large B-Cell Lymphoma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Handa, H; Ito, T | 1 |
| Chen, J; Chen, X; Dou, QP; He, Q; Jiang, L; Lan, X; Liu, J; Shi, X; Sun, Y; Wang, J | 1 |
| Bouabdallah, R; Buchholz, TJ; Carpio, C; Carrancio, S; Cordoba, R; Couto, S; Damian, S; Gandhi, AK; Gharibo, M; Hagner, PR; Hege, K; Lopez-Martin, JA; Martin, A; Panizo, C; Pinto, A; Pourdehnad, M; Rasco, D; Ribrag, V; Risueño, A; Salar, A; Salles, G; Sancho, JM; Santoro, A; Schmitz, F; Trotter, MWB; Van den Neste, E; Verhoef, G; Wang, M; Wang, X; Wei, X; Weng, A; Ysebaert, L | 1 |
| Bijou, F; Bouabdallah, R; Chen, T; Chiappella, A; Doorduijn, JK; Hagner, PR; Hege, K; Kersten, MJ; Klein, C; Mendez, C; Michot, JM; Mosulen, S; Nikolova, Z; Pourdehnad, M; Ribrag, V; Salles, G; Sarmiento, R; Uttamsingh, S; Vitolo, U; Zinzani, PL | 1 |
| Baughman, JM; Fontanillo, C; Jang, IS; Khater, M; Lu, G; Mizukoshi, R; Mo, Z; Namiranian, S; Rolfe, M; Silva-Torres, A; Slade, M; Wang, K; Weng, S; Wood, S | 1 |
| Amantangelo, MD; Barnes, L; Bjorklund, C; Breider, M; Cai, T; Chiu, H; Chopra, R; Couto, S; Daniel, TO; Fontanillo, C; Gandhi, AK; Hagner, PR; Havens, CG; Kang, J; Khambatta, G; Klippel, A; Kosek, J; Lopez-Girona, A; Lu, G; Man, HW; Narla, RK; Pourdehnad, M; Raymon, H; Rychak, E; Schafer, PH; Thakurta, A; Trotter, M; Waldman, M; Wang, M | 1 |
| Nowakowski, GS | 1 |
1 review(s) available for 2-piperidone and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
[Cereblon as a primary target of IMiDs].
Topics: Adaptor Proteins, Signal Transducing; Heterocyclic Compounds, 4 or More Rings; Humans; Immunomodulation; Lupus Erythematosus, Systemic; Lymphoma, Large B-Cell, Diffuse; Morpholines; Peptide Hydrolases; Phthalimides; Piperidones; Protease Inhibitors; Substrate Specificity; Ubiquitin-Protein Ligases | 2019 |
2 trial(s) available for 2-piperidone and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Half-Life; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Piperidones; Quinazolinones; Recurrence; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2020 |
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Interferon Regulatory Factor-7; Interferons; Lenalidomide; Lentivirus; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, SCID; Molecular Mimicry; Peptide Hydrolases; Piperidones; Proteolysis; Quinazolinones; RNA, Small Interfering; Signal Transduction; T-Lymphocytes; Thalidomide; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2015 |
4 other study(ies) available for 2-piperidone and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Cell Movement; Cell Survival; Deubiquitinating Enzymes; Disease Models, Animal; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Nude; Piperidones; Proteasome Inhibitors; Xenograft Model Antitumor Assays | 2019 |
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Drug Resistance, Neoplasm; Female; Humans; Immunophenotyping; Lymphoma, Large B-Cell, Diffuse; Macrophages; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Piperidones; Prognosis; Quinazolinones; Recurrence; Retreatment; T-Lymphocytes; Treatment Outcome | 2020 |
Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Clustered Regularly Interspaced Short Palindromic Repeats; Humans; Lymphoma, Large B-Cell, Diffuse; Piperidones; Potassium Channels; Quinazolinones; Ubiquitin-Protein Ligases | 2021 |
Evolution: IMiDs to PPMs, revolution in DLBCL?
Topics: Animals; Antineoplastic Agents; B-Lymphocytes; Humans; Ikaros Transcription Factor; Lymphoma, Large B-Cell, Diffuse; Peptide Hydrolases; Piperidones; Quinazolinones; Signal Transduction | 2015 |